Erlotinib Completed Phase 1 Trials for Glioblastomas / Gliosarcoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00609999Ph I Dasatinib + Erlotinib in Recurrent MG